KR20070103009A - 뇌혈류를 증가시키는 방법 - Google Patents

뇌혈류를 증가시키는 방법 Download PDF

Info

Publication number
KR20070103009A
KR20070103009A KR1020077017309A KR20077017309A KR20070103009A KR 20070103009 A KR20070103009 A KR 20070103009A KR 1020077017309 A KR1020077017309 A KR 1020077017309A KR 20077017309 A KR20077017309 A KR 20077017309A KR 20070103009 A KR20070103009 A KR 20070103009A
Authority
KR
South Korea
Prior art keywords
seq
blood flow
amino acid
acid sequence
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020077017309A
Other languages
English (en)
Korean (ko)
Inventor
다리아 모클리-로젠
라첼 브라이트
Original Assignee
더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 filed Critical 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티
Publication of KR20070103009A publication Critical patent/KR20070103009A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020077017309A 2005-01-04 2005-12-23 뇌혈류를 증가시키는 방법 Withdrawn KR20070103009A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64141305P 2005-01-04 2005-01-04
US60/641,413 2005-01-04

Publications (1)

Publication Number Publication Date
KR20070103009A true KR20070103009A (ko) 2007-10-22

Family

ID=36692699

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077017309A Withdrawn KR20070103009A (ko) 2005-01-04 2005-12-23 뇌혈류를 증가시키는 방법

Country Status (8)

Country Link
US (2) US7563772B2 (https=)
EP (1) EP1846016A2 (https=)
JP (1) JP2008526750A (https=)
KR (1) KR20070103009A (https=)
CN (1) CN101111257A (https=)
AU (1) AU2005325128A1 (https=)
CA (1) CA2592500A1 (https=)
WO (1) WO2006078421A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057413A2 (en) * 2001-01-18 2002-07-25 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta pkc
US7563772B2 (en) * 2005-01-04 2009-07-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of increasing cerebral blood flow
US20090186814A1 (en) * 2005-01-26 2009-07-23 Fumiaki Ikeno Methods and Compositions for Reducing Ischemia-Derived Microvascular Damage
US20070066526A1 (en) * 2005-09-02 2007-03-22 Daria Mochly-Rosen Method for reducing risk of and extent of injury due to stroke in hypertensive subjects
US7741290B2 (en) * 2006-06-01 2010-06-22 The Board of Trustee of The Leland Stanford Juinior University Method of preventing progression of hypertension-induced heart failure with PKC peptides
AU2007305268A1 (en) * 2006-10-02 2008-04-10 The Board Of Trustees Of The Leland Stanford Junior University Peptides derived from the C2 domain of epsilon PKC, and use thereof
WO2008097563A1 (en) * 2007-02-06 2008-08-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for maintaining blood-brain barrier integrity in hypertensive subjects using a delta-pkc inhibitor
CA2698013A1 (en) * 2007-08-27 2009-03-05 Kai Pharmaceuticals, Inc. Protein kinase c-d inhibitors that protect against cellular injury and inflammation and promote astrocyte proliferation
US20130274651A1 (en) 2012-04-16 2013-10-17 Denise Barbut System and method for improving outcome of cerebral ischemia

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) * 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
CZ280738B6 (cs) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
WO1993007294A1 (en) * 1991-10-01 1993-04-15 The United States Of America, Represented By The Secretary, Department Of Health And Human Service A method of identifying ligands and antagonists of ligands
US5776716A (en) * 1994-02-01 1998-07-07 Terrapin Technologies, Inc. Methods for identifying agents which block the interaction of fyn with PKC-theta, and uses thereof
US5935803A (en) 1994-02-01 1999-08-10 Terrapin Technologies, Inc. Methods to identify immunomodulators using cognate interaction of PKC-theta
US5783405A (en) * 1994-02-01 1998-07-21 Terrapin Technologies, Inc. Rapid screening method for effectors of signal transduction
US5559228A (en) * 1995-03-30 1996-09-24 Eli Lilly And Company Synthesis of bisindolylmaleimides
US6255057B1 (en) * 1996-07-26 2001-07-03 Ernest Gallo Clinic And Research Center Detection of cellular exposure to ethanol
WO1998017299A1 (en) * 1996-10-18 1998-04-30 The Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific activators of protein kinase c, methods and compositions
WO2001028550A1 (en) * 1999-10-15 2001-04-26 Mayo Foundation For Medical Education And Research Topical anesthetics useful for treating cancer, autoimmune diseases and ischemia
WO2001028543A1 (en) 1999-10-15 2001-04-26 Mayo Foundation For Medical Education And Research TREATMENT OF EOSINOPHIL ASSOCIATED PATHOLOGIES BY MODULATING PKC-δ ACTIVITY
WO2001044497A2 (en) * 1999-12-02 2001-06-21 University Of Dundee Protein kinase regulation
US20020048582A1 (en) * 2000-07-18 2002-04-25 King George L. Methods of modulating angiogenesis
WO2002057413A2 (en) * 2001-01-18 2002-07-25 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta pkc
US20030134774A1 (en) * 2001-06-15 2003-07-17 Steinberg Susan F. Methods for inhibiting cardiac disorders
US6933275B2 (en) * 2002-05-01 2005-08-23 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
US20040259816A1 (en) * 2002-10-01 2004-12-23 Pandol Stephen J. Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
JP4567296B2 (ja) * 2003-03-11 2010-10-20 株式会社リコー 電子写真の画像位置検出方法およびこれを用いた記録装置
US20050164324A1 (en) * 2003-06-04 2005-07-28 Gygi Steven P. Systems, methods and kits for characterizing phosphoproteomes
WO2005107789A1 (en) * 2004-04-30 2005-11-17 The Board Of Trustees Of The Leland Stanford Junior University Use of delta pkc peptides for modulation of reactive oxigen species
US7563772B2 (en) * 2005-01-04 2009-07-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of increasing cerebral blood flow

Also Published As

Publication number Publication date
US7563772B2 (en) 2009-07-21
EP1846016A2 (en) 2007-10-24
CN101111257A (zh) 2008-01-23
US20090270328A1 (en) 2009-10-29
CA2592500A1 (en) 2006-07-27
WO2006078421A2 (en) 2006-07-27
WO2006078421A3 (en) 2007-03-22
AU2005325128A1 (en) 2006-07-27
JP2008526750A (ja) 2008-07-24
US8492348B2 (en) 2013-07-23
US20060148702A1 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
US8492348B2 (en) Methods of increasing cerebral blood flow
Wang et al. Dusp14 protects against hepatic ischaemia–reperfusion injury via Tak1 suppression
JP6741642B2 (ja) くも膜下出血および虚血の治療法
JP6319738B2 (ja) 虚血／再灌流障害に続くノーリフローの予防又は処置方法
US10300110B2 (en) Therapy for subarachnoid hemorrhage and ischemia
EP2440231B1 (en) Co-administration of an agent linked to a tat-internalization peptide with a mast cell degranulation inhibitor
EP2568995B1 (en) Therapeutic use of agonists of bradykinin receptor 1 or 2, for modulation collateral blood vessel growth
JP2005523326A (ja) プロテインキナーゼｃのペプチドインヒビター
ES2804424T3 (es) Péptido y composición del mismo para usar en el tratamiento del accidente cerebrovascular con fiebre
US20070066526A1 (en) Method for reducing risk of and extent of injury due to stroke in hypertensive subjects
US20070142272A1 (en) Neuroprotective activity of activated protein c independent of its anticoagulant activity
CA2762338C (en) Therapy for subarachnoid hemorrhage and ischemia
US20090186814A1 (en) Methods and Compositions for Reducing Ischemia-Derived Microvascular Damage
EP1567199B1 (en) Neuroprotective activity of activated protein c is independent of its anticoagulant activity

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070727

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid